Table 3 |
|||||
|
Comparison of PM/Scl-100 antibody-positive versus-negative patients |
|||||
|
Disease manifestation |
anti-PM/Scl-100-positive (n = 20) |
anti-PM/Scl-100-negative (n = 261) |
P value |
Sensitivity, percentagea |
Specificity, percentageb |
|
|
|||||
|
Digital ulcersc |
12 (60.0) |
100 (38.5) |
0.095 |
10.7 |
95.2 |
|
Lung fibrosisc |
11 (55.0) |
87 (33.5) |
0.086 |
11.2 |
95.1 |
|
CK elevationc |
7 (35.0) |
30 (11.5) |
0.009 |
18.9 |
94.7 |
|
Esophago-gastral involvementc |
11 (55.0) |
204 (78.5) |
0.026 |
5.1 |
86.2 |
|
Small intestinal involvementc |
3 (15.0) |
100 (38.5) |
0.052 |
2.9 |
90.4 |
|
Colon involvementc |
4 (20.0) |
115 (44.2) |
0.037 |
3.4 |
90.1 |
|
|
|||||
|
Clinical differences between antibody-positive and -negative patients were shown only when P values of below 0.1 were detected. a,bCalculations of sensitivity and specificity are analogous to those in Table 2. cValues displayed are numbers of patients (percentages). CK, creatine kinase. |
|||||
|
Hanke et al. Arthritis Research & Therapy 2009 11:R22 doi:10.1186/ar2614 |
|||||
